Vascular aging sits at the center of most age-related decline. The endothelium, a single layer of cells lining every blood vessel, loses function over decades. This loss drives arterial stiffness, reduced capillary density, and impaired tissue repair. Two peptides from different research traditions, GHK-Cu (a copper-binding tripeptide) and Vesugen (a short bioregulator peptide), have drawn attention for their effects on vascular biology. GHK-Cu appears to influence collagen remodeling and angiogenic signaling. Vesugen, from the Khavinson peptide school, was originally studied for its effects on blood vessel function. This article reviews published research on both compounds, with reference to related peptides like Epitalon, Cortagen, Pinealon, and Thymalin where relevant. Specific outcomes referenced from studies represent observed effects in defined populations under defined conditions.
Why Endothelial Aging Matters for Longevity
The endothelium is not a passive lining. It regulates vascular tone, prevents thrombosis, and controls the passage of nutrients and immune cells. With age, endothelial cells become senescent or dysfunctional. Nitric oxide production falls. Inflammatory adhesion molecules rise. Capillary networks thin out, especially in skin, brain, and skeletal muscle. These changes precede and predict cardiovascular events, cognitive decline, and poor wound healing. Researchers have measured endothelial dysfunction using flow-mediated dilation, arterial stiffness indices, and circulating markers like asymmetric dimethylarginine. Reversing or slowing endothelial aging is therefore a plausible target for longevity interventions. Peptides that act on endothelial cells or the extracellular matrix around them have become a focus of study. GHK-Cu and Vesugen represent two distinct approaches: one aimed at matrix remodeling and angiogenesis, the other at peptide-mediated regulation of vascular cell function.
GHK-Cu: Copper Peptide and Matrix Remodeling
GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is a naturally occurring tripeptide with a high affinity for copper ions. It was first isolated from human plasma and later found to be released at sites of tissue injury. In cell culture and animal models, GHK-Cu has been shown to stimulate collagen synthesis by fibroblasts, attract immune cells, and promote the growth of new blood vessels. A 2012 review summarized its effects on wound healing, noting that GHK-Cu can increase angiogenesis in a dose-dependent manner. The peptide appears to act in part by modulating the expression of matrix metalloproteinases and their inhibitors, shifting the balance toward tissue remodeling. In skin, GHK-Cu has been studied for its ability to reduce fine lines and improve elasticity, effects that may partly reflect improved microvascular supply. For vascular aging, the relevant question is whether GHK-Cu can restore endothelial function or capillary density in aged tissues. Some animal studies suggest it can, though human data remain limited. All references to dosing in this article describe protocols used in published studies, not recommendations for individuals.
Vesugen: A Short Peptide for Vascular Function
Vesugen is a synthetic tripeptide (Lys-Glu-Asp) developed in the Russian bioregulator tradition. It was designed to target blood vessel function, particularly in the context of age-related vascular pathology. In experimental models, Vesugen has been reported to improve microcirculation, reduce capillary fragility, and normalize endothelial cell metabolism. A 2002 study in rats found that Vesugen administration improved the structure of the vascular wall in aged animals. Another line of research, summarized in a 2013 paper, examined the peptide's effects on endothelial cell cultures, noting changes in gene expression related to vascular tone and inflammation. Unlike GHK-Cu, Vesugen does not carry a metal ion and appears to act through different signaling pathways, possibly involving short peptide regulation of gene transcription. The Khavinson school has long argued that short peptides can interact with DNA or chromatin to modulate gene expression, though this mechanism remains debated outside that tradition.
Comparative Mechanisms: Matrix vs. Cell Signaling
GHK-Cu and Vesugen likely affect the vasculature through different routes. GHK-Cu is a matrix-directed peptide. It binds copper, which is a cofactor for enzymes involved in collagen crosslinking and angiogenesis. It also attracts macrophages and other repair cells to sites of injury. Its effects on endothelial cells may be indirect, mediated by changes in the surrounding extracellular matrix and the release of growth factors from fibroblasts. Vesugen, by contrast, is proposed to act more directly on vascular cells. In the bioregulator framework, short peptides like Vesugen are thought to enter cells and influence the expression of specific genes. Whether this occurs through direct DNA binding, epigenetic modification, or other means is not fully established. What is clear is that the two compounds have different origins and different research literatures. GHK-Cu has been studied mostly in wound healing and cosmetic applications. Vesugen has been studied mostly in Russian-language journals focused on gerontology and vascular pathology. Direct comparative studies are lacking.
Research Findings on GHK-Cu and Vascular Aging
Most GHK-Cu research has focused on skin, but some studies have examined vascular endpoints. In a 2005 study, GHK-Cu was shown to stimulate angiogenesis in a chick chorioallantoic membrane assay. Another 2009 paperShop now!